Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.
about
Betacellulin inhibits osteogenic differentiation and stimulates proliferation through HIF-1alphaHepatocellular carcinoma: Where are we?Pathophysiological mechanisms of death resistance in colorectal carcinomaEGFR signaling promotes β-cell proliferation and survivin expression during pregnancyA ranking method for the concurrent learning of compounds with various activity profiles.Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsA novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activityAn intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle.Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation.Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesYin Yang 1 regulates the transcriptional repression of SurvivinBinding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.Oxygen-carbon nanotubes as a chemotherapy sensitizer for paclitaxel in breast cancer treatment.Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alphaSerum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms.Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis.OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma.Expression of the RNA helicase DDX3 and the hypoxia response in breast cancerIdentification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer.Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.CypA, a gene downstream of HIF-1α, promotes the development of PDACIntegration of CNS survival and differentiation by HIF2α.Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK.Insulin Protects Cardiac Myocytes from Doxorubicin Toxicity by Sp1-Mediated Transactivation of SurvivinRecent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma.Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells.Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity.Hypoxia-inducible factor-1α enhances the malignant phenotype of multicellular spheroid HeLa cells in vitro.Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.The twisted survivin connection to angiogenesisHypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancerMetastasis: recent discoveries and novel treatment strategies.The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma.Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant ChemotherapyKDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
P2860
Q24608282-F5E55529-7658-45EB-A9E1-32F6E5008E86Q26765182-B8031858-43F7-4BEC-9C3A-8C7C12EBBB0DQ26778007-D7B2C031-C91E-4753-9F8F-E30E66E06632Q27346353-4B6B164B-201F-4A5D-81C5-9193E2DAF968Q27902271-3284CDAA-F1D8-4D05-A670-666CB7951F59Q28393898-9AFB73E2-B24D-4CC3-966D-3071A0D4F33FQ28483886-19860510-3C9C-48CA-A7B0-1E3152BE866AQ28485864-BF2EBC04-3855-4A97-8DFF-C7683FC250E5Q30249160-A394E0F1-A9BE-4D0A-9175-90A744136056Q30832574-7B9C9DBA-7F59-4C64-B31F-ACC6E22867C1Q33276827-4A09803D-B4D7-4335-B115-4A8C7E261738Q33644570-23CA0428-0799-4D55-BDB0-BC58AA92AC39Q33730375-DE08F1FC-B3E4-4C46-9C45-4D2570A4E4C3Q33810310-4CDC67A1-5C25-46C2-A57B-3903767D2AF6Q33829321-22FEBDE9-2BF7-4B27-B844-54B0F8BDC3ABQ34000241-0CCE47F1-35B0-4B36-B1B7-FB260A9BEB6FQ34009839-535B124F-346D-4F2C-B958-B41CEDBAB5C4Q34032602-92BC7A3D-214D-4C66-8222-A75C761B2764Q34048283-D73BC8E1-E8FB-4830-A368-3C880A61DFAFQ34427722-89C41681-087C-4840-AF2E-90EA31D35FEDQ34596689-130C1200-5C48-408A-A1F8-8F59E4DF5031Q34733888-C1546B7A-D96C-4004-AACF-921273B6F681Q35030421-3F98E28A-D0BF-4E72-8E13-044B9DB5134AQ35119355-422A0738-0E6E-407C-9BA9-C747F8BCCE9FQ35129112-35653382-1D15-4330-A842-7BD3BA9A6404Q35302094-DC219472-FCC0-4BE6-AA70-9B1FE3EB0411Q35570877-8FEB56B3-68A0-4351-874F-59F6BA4AF04CQ35745202-2592784E-DA05-4D2A-8872-1DB92D760FD9Q35825299-A6DD0D45-776B-4922-AEA7-F37AF5C115C8Q35992790-B874BDEB-48DA-4EA3-B07B-A4D30288BBFCQ35997977-FAE6A03E-6A6B-44D5-A6C5-A4A5E322C4F1Q36216156-4E75E527-5C53-4339-BE4D-A027B821D80FQ36220497-6C14D9B2-8A07-489D-A636-FA6566E0F230Q36262399-9655CA17-B816-40BA-826C-0411FFFDB1C0Q36301932-2C34EA1E-374D-4ED9-8071-7EB0BB6530AAQ36393103-75E3530B-7914-4364-8262-A1F2A0DD2CACQ36407511-3CCBF4F9-0D3E-482C-A7BA-A16A8CC78AB0Q36411703-3D601E61-A42E-4BB2-8EB1-D08FDA0A9C26Q36693275-01BAC06A-5D0D-40EF-A2FE-648232E0E425Q36805595-AE6DDE7A-0D63-46B0-BAFC-C7096FDFCF73
P2860
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cross-talk between epidermal g ...... ting survivin gene expression.
@ast
Cross-talk between epidermal g ...... ting survivin gene expression.
@en
type
label
Cross-talk between epidermal g ...... ting survivin gene expression.
@ast
Cross-talk between epidermal g ...... ting survivin gene expression.
@en
prefLabel
Cross-talk between epidermal g ...... ting survivin gene expression.
@ast
Cross-talk between epidermal g ...... ting survivin gene expression.
@en
P2093
P2860
P356
P1476
Cross-talk between epidermal g ...... ting survivin gene expression.
@en
P2093
Muxiang Zhou
Prasanthi Karna
Xiang-Hong Peng
Zehong Cao
P2860
P304
25903-25914
P356
10.1074/JBC.M603414200
P407
P577
2006-07-17T00:00:00Z